Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants
NCT07339722Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY4515100 (7 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events. Started Jan 2026; status: recruiting.
02
Drugs
LY4515100
Beyond the preview
Go deeper on NCT07339722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339722.